Cancer News and Research

Latest Cancer News and Research

Breast Cancer Research: Thinner girls may be at higher risk of breast cancer

Thinner girls may be at higher risk of breast cancer. Researchers writing in BioMed Central's open access journal Breast Cancer Research found that girls who were leaner at age seven were at higher risk of cancer later in life.

15 Apr 2010

Financial concerns can delay heart attack treatment

A study published Tuesday in the Journal of the American Medical Association reports that financial concerns can lead people having heart attacks to delay treatment.

15 Apr 2010

Study: New anti-cancer agents halt cancer metastasis

ke microscopic inchworms, cancer cells slink away from tumors to travel and settle elsewhere in the body. Now, researchers at Weill Cornell Medical College report in today's online edition of the journal Nature that new anti-cancer agents break down the loping gait these cells use to migrate, stopping them in their tracks.

15 Apr 2010

Australian scientists sequence genome of pancreatic cancer

The International Cancer Genome Consortium which includes researchers from 22 countries is mapping the genomes of different types of cancers. A genome is essentially a blueprint of a human’s DNA. The genetic data of each individual is different and so is the genetic data of the cancer in the individual. The Australian scientists are sequencing the genomes of people suffering from pancreatic cancer.

15 Apr 2010

Men who live further from cities more likely to have chronic health problems and higher death rates, says report

According to a new report from the Australian Institute of Health and Welfare, rural men are more prone to succumb to diseases like diabetes, some cancers like of head, neck and lip, poisonings and chronic health problems compared to those living in major cities.

14 Apr 2010

Foods that protect from Alzheimer’s

In a recent study researchers have revealed what we always knew - salads, fish, fruits and nuts are good for us. It says that these food combinations are related to a reduced risk of getting the dreaded brain and memory disease called Alzheimer’s disease. This study published in the online edition of the reputed journal Archives of Neurology also says that lesser the amount of high-fat dairy foods like butter etc. and red meats, the lesser is the risk of Alzheimer’s disease.

13 Apr 2010

Noncompetitive ''win-win'' relationship between gynecologist and radiologist benefits patients

Journal of Minimally Invasive Gynecology (JMIG) has published a study in its March/April issue which concluded that establishing a referral relationship with an interventional radiologist for comprehensive uterine myoma (fibroid) treatment supports a trusting, collaborative, long-term, noncompetitive ''win-win'' relationship between the gynecologist and radiologist.

13 Apr 2010

Mersana Therapeutics, Teva Pharmaceutical Industries sign research and license agreement

Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer.

13 Apr 2010

Benefits of moderate alcohol drinking on stroke risk counteracted by cigarette smoking

New research finds any beneficial effect of drinking moderate amounts of alcohol on stroke may be counteracted by cigarette smoking, according to research that will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

13 Apr 2010

AACR Annual Meeting 2010: Æterna Zentaris to present data on Erk/PI3K inhibitor compounds

Æterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it will make an oral presentation, as well as a poster presentation on Erk/PI3K inhibitor compounds, Tuesday, April 20, at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 17-21, 2010 at the Walter E. Washington Convention Center in Washington, D.C.

13 Apr 2010

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.

13 Apr 2010

Inflammasome components help protect against colitis

Particular components of inflammasomes-protein complexes needed for generating immune responses to pathogens and cellular damage-lessen the severity of colitis and colitis-associated colon cancer in mice, according to a study published online this week in the Journal of Experimental Medicine.

13 Apr 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research, April 17 – 21, 2010, in Washington, DC.

13 Apr 2010

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.

13 Apr 2010

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

Scientific breakthroughs in molecular targeting, translational cancer research and cancer prevention will take center stage when more than 17,000 scientists from around the world gather at the Walter E. Washington Convention Center, April 17-21, for the AACR 101st Annual Meeting 2010.

13 Apr 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research 101st Annual Meeting 2010 being held April 17-21, 2010, in Washington, D.C.

13 Apr 2010

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

Delcath Systems, Inc., a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO's 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago.

13 Apr 2010

High level of microRNAs found in patients with high-risk multiple myeloma

Multiple myeloma researchers at the University of Arkansas for Medical Sciences (UAMS) recently discovered that widespread activity of a specific class of genes can identify aggressive, or high-risk, cases of the disease.

13 Apr 2010

Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 Apr 2010

Circadian cell division gets disrupted due to artificial light at night

Just one "pulse" of artificial light at night disrupts circadian cell division, reveals a new study carried out by Dr. Rachel Ben-Shlomo of the University of Haifa-Oranim Department of Environmental and Evolutionary Biology along with Prof. Charalambos P. Kyriacou of the University of Leicester. "Damage to cell division is characteristic of cancer, and it is therefore important to understand the causes of this damage," notes Dr. Ben-Shlomo. The study has been published in the journal Cancer Genetics and Cytogenetics.

13 Apr 2010

Cancer News and Research

Latest Cancer News and Research

Breast Cancer Research: Thinner girls may be at higher risk of breast cancer

Financial concerns can delay heart attack treatment

Study: New anti-cancer agents halt cancer metastasis

Australian scientists sequence genome of pancreatic cancer

Men who live further from cities more likely to have chronic health problems and higher death rates, says report

Foods that protect from Alzheimer’s

Noncompetitive ''win-win'' relationship between gynecologist and radiologist benefits patients

Mersana Therapeutics, Teva Pharmaceutical Industries sign research and license agreement

Benefits of moderate alcohol drinking on stroke risk counteracted by cigarette smoking

AACR Annual Meeting 2010: Æterna Zentaris to present data on Erk/PI3K inhibitor compounds

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

Inflammasome components help protect against colitis

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

High level of microRNAs found in patients with high-risk multiple myeloma

Investment report on Rexahn Pharmaceuticals

Circadian cell division gets disrupted due to artificial light at night

Understanding the DNA Damage Response in Innate Immunity eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in